Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MARK3 CRISPR/Cas9 KO Plasmid (h): sc-406362
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MARK3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MARK3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MARK3 Antibody (G-11): sc-365461
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MARK3 CRISPR/Cas9 KO Plasmid (h) | sc-406362 | 20 µg | $397.00 |
Overview
MARK3 (microtubule affinity-regulating kinase 3) is a serine/threonine kinase of the PAR-1/MARK family that phosphorylates microtubule-associated proteins, including tau, to modulate microtubule dynamics and cellular polarity. It functions downstream of polarity-regulating cues and intersects with pathways controlling cytoskeletal remodeling, vesicle trafficking, and cell-cycle progression. Through its roles in neuronal morphogenesis and axon-dendrite specification, dysregulated MARK3 activity has been linked to aberrant tau phosphorylation and neurodegeneration-associated processes. MARK3 is also studied in contexts of epithelial polarity loss and altered migration, where microtubule instability contributes to disease-relevant cellular phenotypes.
MARK3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MARK3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MARK3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MARK3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MARK3 protein expression.
This CRISPR knockout system enables efficient generation of MARK3-deficient cell models for investigation of MARK3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MARK3 exon(s) critical for MARK3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MARK3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MARK3 CRISPR/Cas9 KO Plasmid (h) and MARK3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MARK3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MARK3 HDR Plasmid (h) and MARK3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MARK3 homology arms to support homology-directed repair at defined MARK3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.